8-K

    ========================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


                                  July 7, 2005

                Date of Report (Date of earliest event reported)


                                 ORAGENICS, INC.

             (Exact name of registrant as specified in its charter)


           Florida                  000-50614                59-3410522

(State or other jurisdiction       (Commission              (IRS Employer
      of incorporation)            File Number)          Identification No.)

                            13200 Progress Boulevard
                             Alachua, Florida 32615

           (Address of principal executive offices including zip code)


                                 (386) 418-4018

               Registrant's telephone number, including area code

- --------------------------------------------------------------------------------
                                      None
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)
- --------------------------------------------------------------------------------

   =========================================================================



Item 1.02 Termination of a Material Definitive Agreement

      The Employment Agreement between the Company and Mento A. Soponis dated
January 1, 2004 was terminated in connection with his retirement and resignation
as chief executive officer and president.

Item 5.02 Departure of Director or Principal Officers; Election of Directors;
Appointment of Principal Officers

      On July 6, 2005, Mento A. Soponis resigned as chief executive officer and
president of the Company as a result of his retirement.

      Effective July 6, 2005, Dr. Robert T. Zahradnik has been named acting
president and chief executive officer of the Company replacing Mento A. Soponis.
Mr. Soponis will continue to serve on the Company's Board of Directors and Dr.
Zahradnik has resigned his position on the Board of Directors in order for the
Company to comply with the American Stock Exchange's small business required
ratio of at least 50% of the board being independent board members.

      The Company is currently discussing a severance arrangement with Mr.
Soponis pursuant to the employment agreement terms existing between the Company
and Mr. Soponis. The Company has agreed to a compensation arrangement with Dr.
Zahradnik and the material terms include monthly compensation of $15,000, as
well as medical and dental insurance and retirement compensation consistent with
the Company benefits offered to all employees.

      A copy of the July 6, 2005 press release announcing the appointment of Dr.
Zahradnik as acting chief executive officer and president is attached to this
report as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01 Financial Information and Exhibits

       -------------------- ---------------------------------------
       Exhibit No.          Description
       -------------------- ---------------------------------------
       99.1                 Press Release dated July 6, 2005
       -------------------- ---------------------------------------



                                   SIGNATURES

      In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized on this 7th day of July, 2005.


                             ORAGENICS, INC.
                             (Registrant)

                             BY: /s/ Robert T. Zahradnik
                                 -----------------------
                                 Robert T. Zahradnik
                                 Acting President and Chief Executive Officer

EX-99.1

Contact:

Dr. Robert Zahradnik                                               Joan Kureczka
President and Chief Executive Officer                 Kureczka/Martin Associates
Oragenics, Inc.                                                   (415) 821-2413
(386) 418-4018                                             Jkureczka@comcast.net

FOR IMMEDIATE RELEASE

               Oragenics Names New Interim Chief Executive Officer

ALACHUA, FL (July 6, 2005) - Oragenics, Inc. (AMEX: ONI) today announced that
Dr. Robert T. Zahradnik has been named acting president and chief executive
officer. Dr. Zahradnik replaces Mento A. Soponis who is retiring and has
resigned as an officer of the company. Mr. Soponis will continue to serve on the
company's Board of Directors. The Board is undertaking a search for a new CEO.

Dr. Zahradnik, a co-founder of Oragenics, has been a member of the company's
Board of Directors since November 1996. Prior to rejoining Oragenics, Dr.
Zahradnik spent his career with Johnson & Johnson in various R&D management
positions, with Advanced Clinical Technologies as chairman and CEO, and as
partner and general manager at Pro-Dentec Therapeutics. "The addition of Dr.
Zahradnik to the senior management team, with his extensive experience in
product development, underscores the Company's commitment to broaden its
experience base and prepare for its next stage of growth," commented David J.
Gury, chairman of the Board of Directors.

About Oragenics

Oragenics, Inc. is an emerging biotechnology company focused on the development
and licensure of innovative products and technologies for improving human
health. The company's lead product is a novel oral rinse for the prevention of
tooth decay. The company is also developing a novel antibiotic with
broad-spectrum activity against gram-positive bacteria and a probiotic product
aimed at maintaining oral health. The company is headquartered in Alachua,
Florida. For more information about Oragenics, please consult the company's
website at www.oragenics.com.



Oragenics Names New Interim CEO
Page 2

Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect Oragenics'
current views with respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and assumptions and
information currently available. The words "believe", "expect", "anticipate",
"intend", "estimate", "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to (1)
the ability to successfully complete development and commercialization of
Oragenics' Replacement Therapy for prevention of tooth decay, novel antibiotic,
and probiotic product for oral health; (2) the ability to obtain substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;)4) the ability to develop commercial products with the in-licensed
technology; and (5)) other factors detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements. .


                                      # # #